Isoniazid (INH) and rifampicin (RFP) are the first-line medications for tuberculosis treatment,
and liver injury is the major adverse effect. Natural medicinal ingredients provide distinct …

Myocardial infarction (MI) is considered one of the most common cardiac diseases and
major cause of death worldwide. The prevalence of MI and MI‐associated mortality have …

Tuberculosis (TB), caused by Mycobacterium tuberculosis, continues to pose a significant
threat to global health. The resilience of TB is amplified by a myriad of physical, biological …

Drug-induced liver injury (DILI) remains a critical clinical issue and has been a treatment
challenge today as it was in the past. However, the traditional biomarkers or indicators are …

ABSTRACT Background Single nucleotide polymorphisms (SNPs) in the N-
acetyltransferase 2 (NAT2) gene as well as several other clinical factors can contribute to the …

Molecular-typing can help in unraveling epidemiological scenarios and improvement for
disease control strategies. A literature review of Mycobacterium tuberculosis transmission in …

Isoniazid (INH) is the first-line anti-tuberculosis drug in clinical practice, and its main adverse
effect is drug-induced liver injury (DILI). This study aimed to investigate the hepatoprotective …

Objective Tuberculosis (TB) is a chronic infectious disease which remains a main cause of
death worldwide, and arises more and more concerns in recent years. CytochromeP450 …

目的观察应用水飞蓟宾胶囊联合多烯磷脂酰胆碱治疗抗结核药物所致药物性肝损伤(DILI)
患者的疗效. 方法2018 年6 月~ 2021 年6 月我院收治的118 例肺结核患者, 经标准抗痨治疗后 …

In this chapter, drug‐metabolizing enzymes known to play key roles in the enhancement of
drug toxicity via metabolic activation, and in the reduction of drug toxicity via metabolic …